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Abstract 
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden 
on healthcare resources. 50–80 % patients with chronic migraine have excessive consumption of analgesic medica-
tions. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some head-
ache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine 
attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to 
those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for 
headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The 
data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial 
reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical 
setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.
© 2015 Ahmed et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Chronic migraine (CM), defined as headache on 
≥15 days/month for ≥3 months of which ≥8 days meet 
criteria for migraine with or without aura or responds 
to migraine-specific treatment (IHS 2013). CM is a 
highly disabling primary headache disorder that affects 
approximately 2  % of the general population (Natoli 
et  al. 2010). Patients with CM have reduced quality of 
life (QoL) (Bigal et al. 2008; Lipton et al. 2001); increased 
risk of anxiety, depression and chronic pain (Victor 
et  al. 2010) and use more healthcare resources than 
those with episodic migraine (Blumenfield et  al. 2011). 
CM has significant health, social and economic conse-
quences (Munakata et  al. 2009). Patients with CM are 
advised to treat their headache attacks with analgesics 
and given preventive treatments, taken daily irrespective 
of whether or not headache is present (Mathew 1993). A 
significant proportion of patients with CM have a high 
intake of analgesic medications and around 50–80  % of 
patients with CM attending specialist headache clinic 
have analgesic overuse (Deiner and Limmroth 2004; Bigal 
et  al. 2004). Excessive consumption of analgesics may 
lead to development of medication overuse headache 
(MOH), although it remains uncertain whether this is a 
consequence or a cause of CM (Dodick and Freitag 2006; 
Negro and Martelletti 2011). Many headache experts rec-
ommend withdrawal of the overused medication before 
commencing preventive treatment, although this is not 
based on randomised, placebo-controlled trials (Hagen 
et al. 2009) and for many patients in real life clinical prac-
tice, this is not a pragmatic solution. It is argued that pre-
ventive treatment is only fully effective after stopping the 
overused medication and maximise response to acute 
medication (Zeeberg et al. 2006). The issue of high preva-
lence of analgesic overuse in CM is acknowledged by the 
International Headache Society and allow their inclusion 
in clinical trials provided they are stratified accordingly 
(Silberstein et  al. 2008). In real life and in the absence 
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of robust evidence, the choice of preventive treatment 
before or after withdrawal remains with the treating 
physician.
OnabotulinumtoxinA remains the only licensed medi-
cation for the prevention of CM. Its efficacy and safety 
has been shown in the phase III Research Evaluating 
Migraine Prophylaxis Therapy (PREEMPT) clinical pro-
gramme (Aurora et  al. 2011; Dodick et  al. 2010; Aurora 
et  al. 2010; Diener et  al. 2010; Blumenfield et  al. 2010). 
The sub-group analysis of the PREEMPT data showed 
this to be equally effective in patients with CM with 
medication overuse (Silberstein et  al. 2013). The Hull 
prospective data in real-life clinical practice supported 
PREEMPT findings for the efficacy and safety of Onabot-
ulinumtoxinA as preventive treatment in CM patients 
(Khalil et  al. 2014, 2015). Around 50  % patients in the 
prospective data had medication overuse. This paper 
reports the response to OnabotulinumtoxinA in patients 
with CM with medication overuse in a real-life clinical 
setting.
Methods
The data was collected from the Hull Migraine Clinic 
where patients were treated free of charge on the 
National Health Service (NHS) following recommenda-
tions from the National Institute for Health and Care 
Excellence (NICE) through their technology appraisal 
guidance (TAG260) on the use of OnabotulinumtoxinA 
in adult patients with CM (NICE Technology Appraisal 
guidance 2012). The Hull Migraine Clinic (Hull Royal 
Infirmary and Spire Hospital Hull and East Riding) is a 
tertiary headache centre that sees 1200 new headache 
referrals each year from across the North of England.
Study participants
Adult patients with CM defined by the ICHD II criteria 
(IHS 2004) attending the Hull Migraine Clinic between 1st 
July 2010 and 31st March 2015 were treated with Onabot-
ulinumtoxinA after discussion of all available options. As 
per NICE guidelines, all patients had failed to respond to 
at least three preventive treatments and were treated free 
at the point of entry. Patients were given Onabotulinum-
toxinA based on the clinical needs and were consented to 
receive the treatment based on PREEMPT study protocol 
(Blumenfield et  al. 2010). Patients with analgesic over-
use were offered OnabotulinumtoxinA as recommended 
by the International Headache Society (Silberstein et  al. 
2008). There was no randomisation as the treatment was 
offered solely based on their clinical needs. Only patients 
with complete data were included for analysis. Patients 
were categorised into those with medication overuse 
(MO) and without overuse (WMO).
Medication overuse was defined according to the 
ICHD II. They were categorised as CM with medication 
overuse if:
(a) They had taken simple painkillers (paracetamol/non-
steroidal anti-inflammatory drugs for ≥15 days.
(b) They had taken triptan, combination analgesics, opi-
ates or in combination with simple painkillers for 
≥10 days.
Study design
Patients were injected OnabotulinumtoxinA according to 
the PREEMPT protocol, i.e., 155 units in 31 sites around 
the head and neck (Blumenfield et  al. 2010). Although 
the PREEMPT paradigm allows up to further 45 units on 
the follow the pain sites, none of our patients received 
additional injections. Patients were asked to maintain a 
headache diary for at least 30 days prior to and continu-
ously after receiving treatment. The Hull Headache Diary 
(shown below) (Fig. 1) was used to capture data on head-
ache (Ahmed and Khalil 2013). The continuous diary 
filling was mandatory to assess response to treatment 
in order to determine whether patients were offered a 
repeat treatment. Patients who did not bring their diary 
or filled incompletely were asked to return with further 
4 week of diary recording.
Study measures
Assessments were made from completed diaries for 
headache days, migraine days, headache-free days; also 
of analgesic consumption for all painkillers before and 
after treatment. Quality of life was measured through 
the Headache Impact Test (HIT-6) on the day of treat-
ment and 4 weekly afterwards. Responders were defined 
according NICE criteria i.e., at least 30  % reduction in 
headache days in the month following treatment. How-
ever, as some patients had reported improvement in 
migraine days alone, we evaluated the response based on 
Hull Criteria (Khalil et al. 2014) defined as:
  • 50 % reduction on either headache or migraine days 
OR.
  • Increments in headache free days twice that of the 
baseline in a 30  day period. Those with less than 
3  days of headache free days were only classed as 
responder if they had achieved a minimum of six 
headache free days in the month after treatment.
50 and 75 % responder rates for each of the parameters 
(headache, migraine, headache-free days) were made and 
compared for each group.
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Statistical methods
Data was collected from patients undergoing their first 
full cycle of treatment. Patients were categorised into 
MO and WMO and the effect of treatment in each of 
these groups was examined separately, and a comparison 
of the two groups was also made.
The first analyses compared the differences in out-
comes between measurements made before and after 
treatment for MO and WMO separately. All outcomes 
were measured on a continuous scale. An examination of 
the distribution of these outcomes found that they were 
skewed in their distribution at each set of measurements, 
and in terms of the change in values from pre to post 
treatment. As a result of these skewed distributions, the 
Wilcoxon matched-pairs test was used to compare the 
change in values over time. The analyses were first per-
formed for all patients combined.
Secondly a comparison of the changes from pre to post 
treatment between MO and WMO was made. Due to the 
skewed distribution of the change values, Mann–Whit-
ney test was used for the comparison.
For each patient it was calculated whether they were 
a ‘responder’ based on either a 50  % reduction in the 
number of days with symptoms, or a 75 % decrease. The 
exception was for headache free days where a responder 
was defined by either two-fold or three-fold increase 
in the number of headache free days. The Chi-square 
test was used to compare the proportion of responders 
between MO and NMO.
Hit-6 was used to quantify the change in QoL. The 
HIT-6 score was analysed on a continuous scale, and an 
examination of the change in values over time indicated 
that the changes were normally distributed. As a result 
the paired t test was used to compare the HIT-6 values 
before and after treatment for each group. To compare 
the outcome in the two groups the unpaired t test was 
used due to the normal distribution of the change values.
Results
Demographics and baseline headache characteristics
Of a series of 465 patients, full data on analgesic use 
was available on 434 patients (76 male, mean age 47.5; 
Fig. 1 Hull Headache diary
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range 19–77, 358 females, mean age 44.9; range 18–91). 
Patients had a diagnosis of CM for a mean of 7.4  years 
(range 0.5–67). 219 (50.34  %) patients were overusing 
painkillers (MO). The demographics of the two groups 
are given in Table 1.
Efficacy
Table  2 shows treatment outcome measures in CM 
patients without medication overuse (WMO). The results 
suggest statistically significant differences between the 
before and after treatment measurements for all out-
comes examined.
Table  3 shows treatment outcome measures in CM 
patients with medication overuse (MO). The results 
suggest statistically significant differences between the 
before and after treatment measurements for all out-
comes examined.
The next analyses compared the change in outcomes 
from pre to post treatment between MO and WMO. The 
analysis results are summarised in Table 4, where the fig-
ures are the median (confidence interval) change for each 
group, along with P values indicating the significance of 
the results.
The results suggest no difference in reduction of head-
ache or migraine days in the two groups. The changes in 
crystal clear (headache free days) were similar. Patients 
with medication overuse showed significant reduction 
in consumption of analgesics after treatment for both 
triptans and simple painkillers. However, these results 
should be set in the context of different pre-treatment 
values for painkiller days, with higher pre-treatment 
values for misusers than for non-misusers. Figures  2, 
3, 4 illustrate the outcome on headache, migraine and 
headache free days in the two groups before and after 
treatment.
Table 5 shows a comparison of 50 and 75 % responder 
rate between the two groups. The results show no differ-
ence in reduction of headache and migraine days between 
the two groups. However, patients with medication over-
use had more crystal clear days post-treatment than those 
without medication overuse. This may be attributed to 
fewer crystal clear days before treatment in those with 
medication overuse. Figures  5 and 6 graphically demon-
strate the 50 and 75 % response rate in the two groups.
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Table 2 Outcome from before and after treatment for patients without medication overuse







Headache days 215 26 (20, 30) 17 (11, 28) −5 (−7, −4) <0.001
Migraine days 215 14 (10, 20) 8 (4, 12) −6 (−6, −4) <0.001
Crystal clear days 215 4 (0, 10) 13 (3, 19) 5 (4, 7) <0.001
Painkiller days 215 8 (2,10) 4 (0, 8) −1 (−2, 0) <0.001
Triptan days 215 2 (0, 5) 0 (0, 4) 0 (0, 0) <0.001
Days off work 43 3 (3, 5) 1 (0, 3) −2 (−3, −1) <0.001
Table 3 Outcome from before and after treatment for patients with medication overuse







Headache days 219 28 (24, 30) 20 (12, 26) −7 (−8, −5) <0.001
Migraine days 219 16 (12, 20) 9 (5, 15) −6 (−7, −5) <0.001
Crystal clear days 219 2 (0, 6) 10 (4, 18) 7 (5, 8) <0.001
Painkiller days 219 20 (16, 28) 10 (5, 18) −8 (−9, −6) <0.001
Triptan days 219 6 (0, 12) 2 (0, 7) 0 (−1, 0) <0.001
Days off work 14 4 (2, 8) 2 (0, 4) −2 (−5, 0) 0.04
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Quality of life
Full HIT-6 score was available on 360/434 (82.9  %) 
patients (178 with medication overuse and 182 without 
medication overuse). The results suggested statistically 
significant differences between the before and after treat-
ment scores in patients with or without medication over-
use (see Tables 6, 7). A comparison of the changes from 
pre to post treatment between the two groups is shown in 
Table 8 (also see Fig. 7). The results suggested no strong 
evidence of a significant difference between the two sub-
groups for the change in the HIT-6 score. However, there 
was weak evidence that the reduction was greater in 
patients without medication overuse, although this result 
was not quite statistically significant.
Discussion
Our prospective study provides data from patients 
treated with OnabotulinumtoxinA in a real-life setting 
at a tertiary headache centre in the United Kingdom 
since the publication of the PREEMPT study. The effi-
cacy and safety data on 254 patients with an update on 
465 patients have been presented recently (Khalil et  al. 
2014, 2015). This study reports the outcome on a large 
cohort stratified into those with and without medication 
overuse. However, our cohort in some ways was con-
siderably different to the PREEMPT. All patients in our 
group had failed three preventive treatments based on 
the NICE recommendation for receiving Onabotulinum-
toxinA (only 35 % in PREEMPT); baseline headache days 
were considerably higher in our population (27 versus 
19.9 in PREEMPT) suggesting a more severely affected 
cohort in our study. However only 50 % patients in our 
study fulfilled the criteria for medication overuse (67 % in 
PREEMPT).
Table 4 Comparison of the treatment outcome measures in CM patients with or without medication overuse
Outcome WMO MO P value
Patients (N) Median (95 % CI) Patients (N) Median (95 % CI)
Headache days 215 −5 (−7, −4) 219 −7 (−8, −5) 0.15
Migraine days 215 −6 (−6, −4) 219 −6 (−7, −5) 0.58
Crystal clear days 215 5 (4, 7) 219 7 (5, 8) 0.15
Painkiller days 215 −1 (−2, 0) 219 −8 (−9, −6) <0.001
Triptan days 215 0 (0, 0) 219 0 (−1, 0) <0.001
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Fig. 4 Crystal clear (headache free days) before and after treatment
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The prospective data in this study has shown no sig-
nificant difference in the response to Onabotulinum-
toxinA in patients with CM irrespective of analgesic 
consumption. The results show reduction in headache 
and migraine days before and after treatment in the 
two groups and increment in headache-free (crystal 
clear) days to be similar. The reduction in consumption 
of pain-killers was more in those with medication-over-
use as there were more painkiller days before treatment 
in this group. There was no significant difference in 50 
and 75  % responder rates in the two groups suggest-
ing response to treatment is independent to baseline 
analgesic consumption. However, a two-fold and three-
fold increase in headache-free days was more in the 
medication overuse group even though patients with 
medication overuse had less baseline headache days (26) 
and migraine days (14) than those without medication 
overuse (28 and 16 respectively). The number of head-
ache-free days was also higher in those with medication 
Table 5 50 and  75  % responder rates comparison 
between MO and NMO patients
Outcome Change WMO, N (%) MO, N (%) P value
Headache days ≥50 % 
reduction
55/215 (26 %) 63/219 (29 %) 0.46
≥75 % 
reduction
24/215 (11 %) 22/219 (10 %) 0.71
Migraine days ≥50 % 
reduction
99/215 (46 %) 97/219 (44 %) 0.71
≥75 % 
reduction
14/215 (20 %) 40/219 (18 %) 0.56
Painkiller days ≥50 % 
reduction
64/215 (30 %) 94/219 (43 %) 0.004
≥75 % 
reduction
33/215 (15 %) 44/219 (20 %) 0.20
Triptan days ≥50 % 
reduction
51/215 (24 %) 67/219 (31 %) 0.11
≥75 % 
reduction
26/215 (12 %) 32/219 (15 %) 0.44
Days off work ≥50 % 
reduction
28/43 (65 %) 7/14 (50 %) 0.31
≥75 % 
reduction
19/43 (44 %) 4/14 (29 %) 0.30
Crystal clear days ≥2-fold 
increase





46/215 (21 %) 73/219 (33 %) 0.005







Fig. 5 50 % response on three key outcome parameters







Fig. 6 75 % response on three key outcome parameters
Table 6 HIT-6 scores before  and after  treatment 
in patients without medication overuse
















Table 7 HIT-6 scores before  and after  treatment 
in patients with medication overuse
















Table 8 A comparison of  HIT-6 score before  and 
after treatment between MO and NMO









HIT6 score 182 −8.4 (−9.7, 
−7.1)
178 −6.8 (−8.0, 
−5.6)
0.08
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overuse (4) than those without (2). This may be attrib-
uted to a direct effect on OnabotulinumtoxinA on anal-
gesic consumption. Sandrini et  al. (2011) have shown 
similar response in their cohort of 68 patients in a multi-
centre double-blind, randomised, placebo-controlled, 
parallel group study (Sandrini et al. 2011). An increased 
sensitisation in pain processing (Perrotta et al. 2010) has 
been described in patients with medication overuse, and 
OnabotulinumtoxinA through inhibition of peripheral 
sensitisation (Aoki 2005) may influence central mecha-
nisms responsible for facilitation in pain processing (San-
drini et al. 2011).
The results from this study are also consistent with the 
double-blind, randomised-controlled trial on topiramate 
in patients with CM, where reduction in migraine days 
from baseline were similar irrespective of analgesic con-
sumption (Diener et  al. 2007) and the PREEMPT sub-
group analysis (Silberstein et  al. 2013). This challenges 
the previous notion that preventive therapies are less 
effective in patients with medication overuse (Mathew 
1993; Deiner and Limmroth 2004; Bigal et al. 2004; Kat-
savara et al. 2005).
Our data is prospective and open-label; the treatment 
was given based on the patients’ need and no blinding 
was done. A high placebo-response particularly with 
injectable treatments has been described (Diener et  al. 
2008) although this would have affected both groups 
and not influenced the overall results. In the same way 
improvement due to analgesic withdrawal would have 
been seen purely in the medication overuse group. Our 
patients represent what is seen in an average tertiary 
headache centre; the findings can, therefore, be pro-
jected to what clinicians see in other centres. We identi-
fied medication overuse based on the diary and identified 
painkillers as triptan or non-triptan. We, therefore, do 
not have data on consumption of opiates or other combi-
nation analgesics in our cohort.
Conclusions
Preventive treatment is effective in patients with CM 
with or without medication overuse. Onabotulinum-
toxinA considerably reduces the headache and migraine 
days whilst increasing headache-free days and the benefit 
is equally seen in those with or without co-existing medi-
cation overuse. We acknowledge the value of analgesic 
withdrawal although we suggest that this can be done 
alongside preventive treatment.
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